Bristol Imperial MDMA in Alcoholism Study

Open-label, single-group feasibility study assessing safety and tolerability of MDMA-assisted psychotherapy in patients with alcohol use disorder after detoxification. Participants receive a 10-week psychotherapy course with two MDMA sessions (125 mg plus optional 62.5 mg booster, at sessions 3 and 7).

Outcomes include safety/tolerability, abstinence from alcohol, quality of life and psychosocial functioning; feasibility metrics and adverse events are monitored throughout follow-up.